WithdrawnPhase 2NCT04823052

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Healx Limited
Principal Investigator
Elizabeth Berry-Kravis, M.D
Rush University Medical Center & Children's Hospital
Intervention
Sulindac (HLX-0201), dose strength 1(drug)
Eligibility
13-40 years · MALE
Timeline
20222022

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04823052 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials